Fda approval dates jatenzo kyzatrex tlando?

Fda Approval Dates for Jatenzo and Kysatrex

Both Jatenzo and Kysatrex have received FDA approval. Jatenzo was approved on January 16, 2020 [1]. Kysatrex received its approval on October 20, 2023 [2].

When Did Jatenzo Become Commercially Available?

Following its FDA approval on January 16, 2020, Jatenzo became available to patients. Information regarding its specific market launch date is not provided.

What is Kysatrex Used For?

Kysatrex is indicated for the treatment of adult patients with prostate cancer who have received at least one prior androgen-deprivation therapy and have documented evidence of disease progression [2].

What is Jatenzo Used For?

Jatenzo is prescribed for adults with primary hypertriglyceridemia or mixed dyslipidemia, or very high triglycerides, to reduce cardiovascular risk [1].

Will Jatenzo or Kysatrex Have Patent Expirations Soon?

Patent expiry dates for Jatenzo and Kysatrex are not detailed in the provided information. DrugPatentWatch.com offers resources for tracking pharmaceutical patent expirations [3].

Are There Alternatives to Jatenzo or Kysatrex?

While specific drug-to-drug comparisons are not available, Jatenzo addresses dyslipidemia, and Kysatrex is used in prostate cancer treatment. Alternative treatments exist for both conditions.

Sources:
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=process
[2] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=process
[3] https://drugpatentwatch.com/